417 POSTER Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
European Journal of Cancer Supplements. 2005;3(2):117 
PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE
Value in Health. 2019;22:S466-S467
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
The Breast. 2012;21(1):27-33
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
Breast Cancer Research and Treatment. 2017;163(3):635-635
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Cancer Research and Treatment. 2017;49(2):454-463
Cost-Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced/Metastatic Breast Cancer from A UK National Health Service Perspective
Value in Health. 2017;20(9):A433
5048 A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR+) metastatic breast cancer (MBC)
European Journal of Cancer Supplements. 2009;7(2):275
Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
Therapeutic Advances in Medical Oncology. 2021;13:175883592110005
PR86 RETROSPECTIVE STUDY OF EVEROLIMUS WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER PRETREATED WITH AROMATASE INHIBITORS(AI'S) AND SELECTIVE ESTROGEN MODIFIERS
The Breast. 2015;24:S51
breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)
Annals of Oncology. 2016;27:vi553